Sentiment Trading

GeoVax Labs Inc. reported its first quarter 2025 financial results, highlighting progress on its COVID-19 vaccine, Mpox and Smallpox vaccine, and gene-directed enzyme prodrug therapy for cancer treatment.

GeoVax Labs Inc faces financial turmoil, but its recent clinical developments, particularly with Gedeptin, offer a glimmer of hope for the company’s future.

GeoVax Labs Inc. showcases strong clinical results for its COVID-19 vaccine candidate, GEO-CM04S1, and announces key appointments, including a new Vice President of Technical Development, as the company prepares to report its Q1 2025 financial results.